Evidence map›Paper›PMID 29280917›Full record

ArticleEar and hearing

Long-Term Variability of Distortion-Product Otoacoustic Emissions in Infants and Children and Its Relation to Pediatric Ototoxicity Monitoring.

Dawn Konrad-Martin, Kristin Knight, Garnett P McMillan, Laura E Dreisbach, Elsa Nelson, Marilyn Dille

Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in Ear and hearing. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02099786 (Comprehensive Ototoxicity Monitoring Program for VA), which is not on this map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02099786 nacompletednot on this map

Comprehensive Ototoxicity Monitoring Program for VA: A Randomized Trial

TypeinterventionalSponsorVA Office of Research and DevelopmentRan2015 to 2018Enrolled47ConditionsCisplatin Ototoxicity, Hearing LossArmsCOMP-VA, Standard of care
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. What's New in Ototoxicity Management?Perspectives of the ASHA special interest groups · 2024
    Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Dawn Konrad-MartinUnited States (U.S.) Department of Veterans Affairs (VA), Office of Rehabilitation Auditory Research (RR&D) Services, National Center for Rehabilitative Auditory Research (NCRAR), VA Portland, and Healthcare System (VAPORHCS), Portland, Oregon, USA.
Kristin KnightDepartment of Pediatric Audiology, Oregon Health & Science University, Portland, Oregon, USA.
Garnett P McMillanUnited States (U.S.) Department of Veterans Affairs (VA), Office of Rehabilitation Auditory Research (RR&D) Services, National Center for Rehabilitative Auditory Research (NCRAR), VA Portland, and Healthcare System (VAPORHCS), Portland, Oregon, USA.
Laura E DreisbachSchool of Speech, Language, and Hearing Sciences, San Diego State University, San Diego, California, USA.
Elsa NelsonDepartment of Pediatric Audiology, Oregon Health & Science University, Portland, Oregon, USA.
Marilyn DilleUnited States (U.S.) Department of Veterans Affairs (VA), Office of Rehabilitation Auditory Research (RR&D) Services, National Center for Rehabilitative Auditory Research (NCRAR), VA Portland, and Healthcare System (VAPORHCS), Portland, Oregon, USA.
Oregon Health & Science University · USSan Diego State University · USUnited States Department of Veterans Affairs · US

Funding

Individualized Objective Techniques for Early Detection of OtotoxicityI01RX000239 · VA · PORTLAND VA MEDICAL CENTER · PI DILLE, MARILYN F., KONRAD-MARTIN, DAWN L · 2011 to 2017
–
RRD VA I01 RX000239RRD VA I50 RX002361
6 · The paper itself

Abstract

objectiveDistortion-product otoacoustic emissions (DPOAEs) provide a rapid, noninvasive measure of outer hair cell damage associated with chemotherapy and are a key component of pediatric ototoxicity monitoring. Serial monitoring of DPOAE levels in reference to baseline measures is one method for detecting ototoxic damage. Interpreting DPOAE findings in this context requires that test-retest differences be considered in relation to normal variability, data which are lacking in children. This study sought to (1) characterize normal test-retest variability in DPOAE level over the long time periods reflective of pediatric chemotherapy regimens for a variety of childhood ages and f2 primary frequencies using common clinical instrumentation and stimulus parameters; (2) develop level-shift reference intervals; and (3) account for any age-related change in DPOAE level or measurement error that may occur as the auditory system undergoes maturational change early in life.

designSerial DPOAE measurements were obtained in 38 healthy children (25 females and 13 males) with normal hearing and ranging in age from one month to 10 years at the initial (baseline) visit. On average, children were tested 5.2 times over an observation period of 6.5 months. Data were collected in the form of DP grams, in which DPOAE level was measured for f2 ranging from 1.4 to 10 kHz, using a fixed f2/f1 ratio of 1.22 and stimulus level of 65/55 dB SPL for L1/L2. Age effects on DPOAE level and measurement error were estimated using Bayesian regression of the longitudinal data. The raw and model-based distribution of DPOAE test-retest differences were characterized using means and standard error of the measurement for several ages and f2's.

resultsDPOAE test-retest differences for the children in this study are at the high end of those previously observed in adults, as reflected in the associated shift reference intervals. Further, although we observe substantial child-specific variation in DPOAE level, the pattern of age-related changes is highly consistent across children. Across a wide range of f2's, DPOAE level decreases by 3 to 4 dB from 1 to 13 months of age followed by a more gradual decline of <1 dB/year. An f2 of 6 kHz shows the smallest decrease during the early rapid maturation period. DPOAE measurement error is fairly constant with age. It is 3 to 4 dB at most f2's and is greater (indicating poorer reliability) at 1.5, 8, and 10 kHz.

conclusionsDPOAE level decreases with childhood age, with the greatest changes observed in the first year of life. Maturational effects during infancy and greater measurement error at very low and high f2's affect test-retest variability in children. An f2 of 6 kHz shows minimal maturation and measurement error, suggesting it may be an optimal sentinel frequency for ototoxicity monitoring in pediatric patients. Once validated with locally developed normative data, reference intervals provided herein could be used to determine screen fail criteria for serial monitoring using DPOAEs. Employing state-of-the-art calibration techniques might reduce variability, allowing for more sensitive screen fail criteria.

Indexed as

OtotoxicityAdultBayes TheoremChildFemaleHumansMaleOtoacoustic Emissions, SpontaneousReference ValuesReproducibility of Results

Identifiers

PMID29280917
PMCPMC6504621
OpenAlexW2780790272

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.